[go: up one dir, main page]

ATE155042T1 - Warm-behandelte igm-antikörper-zusammensetzungen - Google Patents

Warm-behandelte igm-antikörper-zusammensetzungen

Info

Publication number
ATE155042T1
ATE155042T1 AT91104391T AT91104391T ATE155042T1 AT E155042 T1 ATE155042 T1 AT E155042T1 AT 91104391 T AT91104391 T AT 91104391T AT 91104391 T AT91104391 T AT 91104391T AT E155042 T1 ATE155042 T1 AT E155042T1
Authority
AT
Austria
Prior art keywords
igm
warm
igm antibodies
concentrates
antibodies compositions
Prior art date
Application number
AT91104391T
Other languages
English (en)
Inventor
Grace C Tsay
Gary Jesmok
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of ATE155042T1 publication Critical patent/ATE155042T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/806—Drug, bio-affecting and body treating compositions involving IgM
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT91104391T 1990-04-03 1991-03-21 Warm-behandelte igm-antikörper-zusammensetzungen ATE155042T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/504,161 US5256771A (en) 1990-04-03 1990-04-03 Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation

Publications (1)

Publication Number Publication Date
ATE155042T1 true ATE155042T1 (de) 1997-07-15

Family

ID=24005109

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91104391T ATE155042T1 (de) 1990-04-03 1991-03-21 Warm-behandelte igm-antikörper-zusammensetzungen

Country Status (9)

Country Link
US (3) US5256771A (de)
EP (1) EP0450412B1 (de)
JP (1) JP3591782B2 (de)
AT (1) ATE155042T1 (de)
CA (1) CA2039387C (de)
DE (1) DE69126727T2 (de)
DK (1) DK0450412T3 (de)
ES (1) ES2104625T3 (de)
GR (1) GR3024910T3 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297024B1 (en) 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
US6235494B1 (en) 1999-02-08 2001-05-22 The Scripps Research Institute Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
AU2004247021A1 (en) * 2003-05-16 2004-12-23 Acorda Therapeutics Compositions and methods including a recombinant human MAB that promotes CNS remyelination
GB0425537D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Process for obtaining antibodies
GB201006753D0 (en) * 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
FR2959821B1 (fr) 2010-05-05 2012-07-06 Lab Francais Du Fractionnement Procede de mesure de l'activation du complement par des igg
EP3275897A1 (de) 2016-07-27 2018-01-31 Biotest AG Verfahren zur herstellung von immunoglobulinzusammensetzungen
US11401337B2 (en) 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
CA3183021A1 (en) * 2020-07-10 2022-01-13 Myles Lindsay Method for obtaining a composition comprising human plasma-derived immunoglobulin m

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2527064C3 (de) * 1975-06-18 1979-11-15 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung eines intravenösen Nativ-Human-Immunglobulin-Präparates mit natürlicher Halbwertszeit und gegenüber dem Ausgangsmaterial unveränderten Antikörperaktivität
DE2835843A1 (de) * 1978-08-16 1980-02-28 Blutspendedienst Dt Rote Kreuz Verfahren zur herstellung einer fuer die intravenoese anwendung geeigneten gammaglobulinloesung
DE2901822A1 (de) * 1979-01-18 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt
JPS56147724A (en) * 1980-04-18 1981-11-16 Teijin Ltd Igm derivative and immunoglobulin preparation for intravenous injection containing said compound as effective component
JPS57140724A (en) * 1981-02-25 1982-08-31 Green Cross Corp:The Heat-treatment of aqueous solution containing cold insoluble globulin
EP0085747B2 (de) * 1982-02-08 1990-05-30 Schweizerisches Serum- und Impfinstitut und Institut zur Erforschung der Infektionskrankheiten Intravenös verabreichbares humanes Immunglobulin und Verfahren zu dessen Herstellung
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
DE3927111C3 (de) * 1989-08-17 1994-09-01 Biotest Pharma Gmbh Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate

Also Published As

Publication number Publication date
DE69126727D1 (de) 1997-08-14
EP0450412B1 (de) 1997-07-09
JPH04221321A (ja) 1992-08-11
US5612033A (en) 1997-03-18
CA2039387C (en) 2002-02-19
US5510465A (en) 1996-04-23
ES2104625T3 (es) 1997-10-16
CA2039387A1 (en) 1991-10-04
DK0450412T3 (da) 1998-02-16
JP3591782B2 (ja) 2004-11-24
US5256771A (en) 1993-10-26
GR3024910T3 (en) 1998-01-30
DE69126727T2 (de) 1997-10-23
EP0450412A1 (de) 1991-10-09

Similar Documents

Publication Publication Date Title
Soltis et al. The effect of heat inactivation of serum on aggregation of immunoglobulins
Ishizaka et al. Triggering of histamine release from rat mast cells by divalent antibodies against IgE-receptors
Ishizaka et al. Immune mechanisms of reversed type reaginic hypersensitivity
Geltner et al. Antiidiotypic activity in the IgM fractions of mixed cryoglobulins.
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
ATE128732T1 (de) Antigenkonstrukte von ''major histocompatibility complex'' klasse i antigenen mit spezifischen trägermolekülen, ihre herstellung und verwendung.
KR890701632A (ko) 사람 인터루킨-4에 대한 모노클로날 항체 및 이를 생성하는 하이브리도마
EP0091760A1 (de) Anti-Immunkomplex-Antikörper und Verfahren zur Herstellung desselben
ATE155042T1 (de) Warm-behandelte igm-antikörper-zusammensetzungen
AU619183B2 (en) A one-step immunoassay for the determination of antigen-specific antibodies of one of the immunoglobulin classes a,m,d or e, and an agent suitable for this purpose
FI903827A0 (fi) Foerfarande foer reducering av immunoglobulin e-responser.
Prouvost-Danon et al. Mouse and rat IgE Cross-sensitization of mast cells and antigenic relationships
ZA9210006B (en) Anti-human IgE monoclonal antibodies.
DE10299038I2 (de) Pl{ttchen-spezifisches Chim{risches immunglobulin.
Grant et al. Reversed in vitro anaphylaxis induced by anti-IgG: specificity of the reaction and comparison with antigen-induced histamine release
Knight et al. Distribution of covalently bound and non-covalently bound secretory component on subclasses of rabbit secretory IgA
Edwards et al. Pseudoimmune precipitation by the isolated byssinosis “antigen”
Gold et al. Experimental studies on the mechanism of induction of anti-nuclear antibodies by procainamide
DE3851492D1 (de) Ein gattungsspezifisches Listeria-Antigen, identifiziert durch monoklonale Antikörper.
Wilkerson et al. Anti‐A isoagglutinins in two blood type B cats are IgG and IgM
Isliker et al. The structure and biological activity of immunoglobulins and their subunits
Lang et al. Production of goat, rat, and guinea pig antisera to murine IgE
Onicǎ et al. Antigenic specificity of glutaraldehyde-treated rabbit albumin
Lang et al. Murine and rat IgE: Relationships in terms of binding to cell receptors and to antibodies against rat epsilon chain
Stux et al. Heterogeneity of rabbit homologous skin sensitizing antibodies: IgE and a new subclass IgGa

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time